Seelos Therapeutics (OTCPK:SEEL) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SEEL Overzicht aandelen

Seelos Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van therapeutica voor de behandeling van aandoeningen van het centrale zenuwstelsel en andere aandoeningen.

Over het bedrijf

SEEL fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	2/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De koers-winstverhouding ( 0.3 x) ligt onder de US markt ( 18.3 x)

Dit jaar winstgevend geworden

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $2M )

De schulden worden niet goed gedekt door de operationele kasstroom

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

+ 3 meer risico's

Seelos Therapeutics, Inc. Concurrenten

Evofem Biosciences

OTCPK:EVFM

US$973.2k

CannaPharmaRX

OTCPK:CPMD

US$7.2m

Kiora Pharmaceuticals

NasdaqCM:KPRX

US$9.8m

Kaya Holdings

OTCPK:KAYS

US$849.8k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Seelos Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$1.01
52 Week Hoogtepunt	US$848.64
52 Week Laag	US$0.82
Bèta	1.85
11 maand verandering	-68.29%
3 maanden verandering	-88.44%
1 Jaar Verandering	-99.87%
33 jaar verandering	-99.99%
5 jaar verandering	-99.97%
Verandering sinds IPO	-99.99%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	SEEL	US Pharmaceuticals	US Markt
7D	-58.4%	1.3%	1.1%
1Y	-99.9%	23.2%	36.0%

Rendement versus industrie: SEEL presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 23.1 % opleverde.

Rendement versus markt: SEEL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is SEEL's price volatile compared to industry and market?
SEEL volatility
SEEL Average Weekly Movement	32.3%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SEEL is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SEEL is het afgelopen jaar gestegen van 24% naar 31%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	8	Raj Mehra	seelostherapeutics.com

Seelos Therapeutics, Inc, een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van therapeutica voor de behandeling van aandoeningen van het centrale zenuwstelsel en andere aandoeningen. De belangrijkste programma's van het bedrijf zijn SLS-002, een intranasale racemische ketamine voor de behandeling van acute suïcidale gedachten en gedrag bij patiënten met depressieve stoornissen; SLS-004, een gentherapie gericht tegen gen- en alfa-synucleïne; SLS-005, een proteïnestabilisator voor de behandeling van amyotrofische laterale sclerose en het Sanfilippo-syndroom; SLS-007, een peptidische remmer voor de ziekte van NACore Parkinson; en SLS-009, een proteïnegerichte autofagie voor de ziekte van Alzheimer. Seelos Therapeutics, Inc. werd opgericht in 2016 en het hoofdkantoor is gevestigd in New York, New York.

Seelos Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Seelos Therapeutics zich tot de beurswaarde?
SEEL fundamentele statistieken
Marktkapitalisatie	US$518.79k
Inkomsten(TTM)	US$4.09m
Inkomsten(TTM)	US$2.01m

0.1x

Koers/Winstverhouding

0.2x

P/S-verhouding

Is SEEL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SEEL resultatenrekening (TTM)
Inkomsten	US$2.01m
Kosten van inkomsten	US$20.45m
Brutowinst	-US$18.43m
Overige uitgaven	-US$22.53m
Inkomsten	US$4.09m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	9.38
Brutomarge	-915.34%
Nettowinstmarge	203.13%
Schuld/Eigen Vermogen Verhouding	-35.9%

Hoe presteerde SEEL op de lange termijn?

Bekijk historische prestaties en vergelijking

SEEL Overzicht aandelen

Beloningen

Risicoanalyse

Seelos Therapeutics, Inc. Concurrenten

OTCPK:EVFM

US$973.2k

OTCPK:CPMD

US$7.2m

NasdaqCM:KPRX

US$9.8m

OTCPK:KAYS

US$849.8k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Recent updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors